Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Fortical (Calcitonin) – US: CAFC affirms summary judgment of nonobviousness of Fortical formulation: Unigene v Apotex (Orange Book Blog) (Patent Docs) (IPBiz)

US: Google to pay $500 million regarding pharmacy advertising; What is next? (FDA Law Blog) (Out-Law)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

The patentability black hole (Patent Law Practice Center)

Notes on the new Wikileaks cables – Pfizer asks US embassy to intervene in Philippines drug prices debate, US-Thailand FTA concerns, etc (KEI)

240 Wikileaks cables on pharmaceutical data exclusivity (KEI)

2,446 Wikileaks cables mentioning the search term “pharmaceutical” (KEI)

Australia: Gene Patent Bill update – Senate inquiry extended… again (Patentology)

EU: Post-Medeva analysis: the dialogue continues (The SPC Blog)

US / Guatamala: From Wikileaks, a US government cable on its involvement to shape Guatemala legislation on pharmaceutical IPR (KEI)

US / India: Wikileaks on USTR negotiations with India Minister Sharma (KEI)

US: Plaintiff(s) file petition for rehearing AMP v USPTO (Patent Docs) (Patent Docs)

US: Defendants file petition for rehearing in AMP v USPTO (Patent Docs)

US: Google to pay $500 million regarding pharmacy advertising; What is next? (FDA Law Blog) (Out-Law)

US: FDA maintains that preparation of an NDI notification takes 20 hours (FDA Law Blog)

US: Public Citizen petitions FDA to amend generic drug labeling regulations in the wake of Mensing (FDA Law Blog)

 

Products

Combigan (Brimonidine, Timolol) – US: Allergan secures infringement ruling against generics in Combigan patent suit (Patent Docs)

Copaxone (Glatiramer acetate) – US: Teva suit against generic Momenta over Copaxone proceeds in SDNY (IPBiz)

Ebastel (Ebastine) – Belgium: Antwerp Court of Appeal dismisses Almirall’s claims against Teva – Precipitation is no micronization (Kluwer Patent Blog)

Famvir (Famciclovir) – US: Novartis settles with Macleods in Famvir patent dispute (Patent Docs)

Fortical (Calcitonin) – US: CAFC affirms summary judgment of nonobviousness of Fortical formulation: Unigene v Apotex (Orange Book Blog) (Patent Docs) (IPBiz)

Hectorol (Doxercalciferol) – US: ANDA case stayed pending reexam: Genzyme v Cobrek (Chicago Intellectual Property Law Blog)

Memantine – Germany: BGH: does an explanation make an invention? X ZR 68/08 (IPKat)

Myfortic (Mycophenolate sodium) – US: Novartis and Apotex resolve patent dispute over Myfortic (Patent Docs)

Ofirmev (Acetaminophen) – US: Cadence Pharmaceuticals files patent infringement suits in W D North Carolina, W D Michigan, Minnesota and Delaware against Exela, Paddock and Perrigo following Para IV certification (Patent Docs)

Patanase (Olopatadine) – US: Alcon files patent infringement suit against Apotex in response to Para IV certification (Patent Docs)

ReFacto (Moroctocog alfa) – US: CAFC affirms dismissal of Factor VIII priority case for lack of interfering subject matter: Genetics Institute v Novartis Vaccines & Diagnostics (Orange Book Blog) (Patently-O)